Abstract
Peripheral arterial occlusive disease (PAOD) is now recognized as a combination of clinical syndromes that are associated with significant morbidity and mortality. The primary pathophysiology of PAOD is impaired perfusion to the lower extremity. Effective pharmacotherapy designed to increase perfusion in PAOD is lacking, and revascularization options are suboptimal. New and more efficacious therapies that improve blood flow are definitely needed, and thus designing, describing, and validating these new therapies in preclinical PAOD models will be essential. This study describes the various preclinical PAOD models presently in use, correlates the models to human PAOD, and reviews the available end points that can be used to detect a response to therapy.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 773-780 |
| Number of pages | 8 |
| Journal | Journal of Applied Physiology |
| Volume | 97 |
| Issue number | 2 |
| DOIs | |
| State | Published - Aug 2004 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Angiogenesis
- Endothelial cells
- Growth factors
- Perfusion
- Vascular surgery
ASJC Scopus subject areas
- General Medicine
Fingerprint
Dive into the research topics of 'Preclinical models of human peripheral arterial occlusive disease: Implications for investigation of therapeutic agents'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS